Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Elanco representative appointed as Neurizon Board observer

13 August 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Dr. Steve Nanchen as a Board Observer.

Dr. Nanchen has been appointed as Elanco Animal Health's ("Elanco") designated representative and succeeds Ms. Justine Conway, who recently transitioned to pursue new opportunities.

The appointment reflects the continued strength of the strategic relationship between Neurizon and Elanco, following the exclusive global license agreement for monepantel, the active pharmaceutical ingredient in NUZ-001, together with the recently announced long-term supply agreement. Collectively, these agreements provide Neurizon with secure access to both the intellectual property and future commercial supply of GMP monepantel, while also providing access to a substantial package of animal safety, manufacturing and regulatory data to support the Company's clinical development, regulatory strategy and potential future commercialisation objectives..

Dr Nanchen serves as Senior Advisor, External Innovation at Elanco Animal Health. He has nearly 20 years of experience across the animal health and pharmaceutical industries, with extensive expertise in research and development, external innovation and strategic partnerships. During his career with Elanco and Novartis Animal Health, he has led global research programs and high-value licensing transactions. Dr Nanchen is also one of the inventors of lotilaner (Credelio®) and holds a PhD in Organic Chemistry from the University of Basel, together with a postdoctoral fellowship at Stanford University.

His appointment demonstrates the continued engagement between Neurizon and Elanco as the Company advances NUZ-001 through the HEALEY ALS Platform Trial and evaluates broader opportunities across neurodegenerative diseases.

As Board Observer, Dr. Nanchen will be entitled to attend and participate in Board and committee meetings but will not hold voting rights.

Interim Executive Chairman, Sergio Duchini, said: *"On behalf of the Board, I would like to welcome Steve to Neurizon and thank Justine for her valuable contribution over the past year.*

Elanco remains one of Neurizon's most important strategic partners, with the combination of our licence and long-term supply agreements reflecting the commitment to the successful development of NUZ-001, and to this end we are pleased to see that commitment continue through Steve's appointment as Board Observer.

He brings an outstanding combination of scientific, commercial and strategic expertise, having played leading roles in research and development, external innovation and licensing across the global animal health industry. His experience and deep understanding of monepantel will be highly valuable as we continue to progress NUZ-001 through clinical development.

Steve joins the Neurizon Board at an exciting time for the Company as we continue to advance NUZ-001 through the HEALEY ALS Platform Trial and pursue our vision of establishing NUZ-001 as a potential treatment option across multiple neurodegenerative diseases.

I would also like to sincerely thank Justine for her support, guidance and contribution to Neurizon. We wish her every success in the future."

-ENDS-

This announcement has been authorised for release by the Interim Executive Chairman on behalf of the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Neurizon Therapeutics
Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Australia Investor Relations
Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com